OBJECTIVE: Pulmonary complications, including pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH), are the leading cause of mortality in patients with systemic sclerosis (SSc). The aim of this study was to compare the molecular fingerprint of lung tissue and matching primary fibroblasts from patients with SSc with that of lung tissue and fibroblasts from normal donors, patients with idiopathic pulmonary fibrosis (IPF), and patients with idiopathic pulmonary arterial hypertension (IPAH). METHODS: Lung tissue samples were obtained from 33 patients with SSc who underwent lung transplantation. Tissues and cells from a subgroup of SSc patients with predominantly PF or PAH were compared to those from normal donors, patients with IPF, and patients with IPAH. Microarray data were analyzed using efficiency analysis for determination of the optimal data-processing methods. Real-time polymerase chain reaction and immunohistochemistry were used to confirm differential levels of messenger RNA and protein, respectively. RESULTS: Consensus efficiency analysis identified 242 and 335 genes that were differentially expressed in lungs and primary fibroblasts, respectively. SSc-PF and IPF lungs shared enriched functional groups in genes implicated in fibrosis, insulin-like growth factor signaling, and caveolin-mediated endocytosis. Gene functional groups shared by SSc-PAH and IPAH lungs included those involved in antigen presentation, chemokine activity, and interleukin-17 signaling. CONCLUSION: Using microarray analysis on carefully phenotyped SSc and comparator lung tissues, we demonstrated distinct molecular profiles in tissues and fibroblasts from patients with SSc-associated lung disease compared to idiopathic forms of lung disease. Unique molecular signatures were generated that are disease specific (SSc) and phenotype specific (PF versus PAH). These signatures provide new insights into the pathogenesis and potential therapeutic targets of SSc-related lung disease.
OBJECTIVE: Pulmonary complications, including pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH), are the leading cause of mortality in patients with systemic sclerosis (SSc). The aim of this study was to compare the molecular fingerprint of lung tissue and matching primary fibroblasts from patients with SSc with that of lung tissue and fibroblasts from normal donors, patients with idiopathic pulmonary fibrosis (IPF), and patients with idiopathic pulmonary arterial hypertension (IPAH). METHODS: Lung tissue samples were obtained from 33 patients with SSc who underwent lung transplantation. Tissues and cells from a subgroup of SSc patients with predominantly PF or PAH were compared to those from normal donors, patients with IPF, and patients with IPAH. Microarray data were analyzed using efficiency analysis for determination of the optimal data-processing methods. Real-time polymerase chain reaction and immunohistochemistry were used to confirm differential levels of messenger RNA and protein, respectively. RESULTS: Consensus efficiency analysis identified 242 and 335 genes that were differentially expressed in lungs and primary fibroblasts, respectively. SSc-PF and IPF lungs shared enriched functional groups in genes implicated in fibrosis, insulin-like growth factor signaling, and caveolin-mediated endocytosis. Gene functional groups shared by SSc-PAH and IPAH lungs included those involved in antigen presentation, chemokine activity, and interleukin-17 signaling. CONCLUSION: Using microarray analysis on carefully phenotyped SSc and comparator lung tissues, we demonstrated distinct molecular profiles in tissues and fibroblasts from patients with SSc-associated lung disease compared to idiopathic forms of lung disease. Unique molecular signatures were generated that are disease specific (SSc) and phenotype specific (PF versus PAH). These signatures provide new insights into the pathogenesis and potential therapeutic targets of SSc-related lung disease.
Authors: Todd M Bull; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; David V Pham; S Patrick Nana-Sinkam; Norbert F Voelkel; Mark W Geraci Journal: Am J Respir Crit Care Med Date: 2004-06-23 Impact factor: 21.405
Authors: Aryeh Fischer; Jeffrey J Swigris; Steve D Groshong; Carlyne D Cool; Hakan Sahin; David A Lynch; Douglas Curran-Everett; JoAnn Z Gillis; Richard T Meehan; Kevin K Brown Journal: Chest Date: 2008-04-10 Impact factor: 9.410
Authors: Xiao Mei Wang; Yingze Zhang; Hong Pyo Kim; Zhihong Zhou; Carol A Feghali-Bostwick; Fang Liu; Emeka Ifedigbo; Xiaohui Xu; Tim D Oury; Naftali Kaminski; Augustine M K Choi Journal: J Exp Med Date: 2006-12-18 Impact factor: 14.307
Authors: Elisabetta A Renzoni; David J Abraham; Sarah Howat; Xu Shi-Wen; Piersante Sestini; George Bou-Gharios; Athol U Wells; Srihari Veeraraghavan; Andrew G Nicholson; Christopher P Denton; Andrew Leask; Jeremy D Pearson; Carol M Black; Kenneth I Welsh; Roland M du Bois Journal: Respir Res Date: 2004-11-30
Authors: Yasmina Bauer; John Tedrow; Simon de Bernard; Magdalena Birker-Robaczewska; Kevin F Gibson; Brenda Juan Guardela; Patrick Hess; Axel Klenk; Kathleen O Lindell; Sylvie Poirey; Bérengère Renault; Markus Rey; Edgar Weber; Oliver Nayler; Naftali Kaminski Journal: Am J Respir Cell Mol Biol Date: 2015-02 Impact factor: 6.914
Authors: Shibnath Ghatak; Galina S Bogatkevich; Ilia Atnelishvili; Tanjina Akter; Carol Feghali-Bostwick; Stanley Hoffman; Victor M Fresco; John C Fuchs; Richard P Visconti; Roger R Markwald; Subhas B Padhye; Richard M Silver; Vincent C Hascall; Suniti Misra Journal: J Biol Chem Date: 2013-12-09 Impact factor: 5.157
Authors: Angela Ghatnekar; Izabela Chrobak; Charlie Reese; Lukasz Stawski; Francesca Seta; Elaine Wirrig; Jesus Paez-Cortez; Margaret Markiewicz; Yoshihide Asano; Russell Harley; Richard Silver; Carol Feghali-Bostwick; Maria Trojanowska Journal: Am J Pathol Date: 2013-04-11 Impact factor: 4.307
Authors: Rana Herro; Haruka Miki; Gurupreet S Sethi; David Mills; Amit Kumar Mehta; Xinh-Xinh Nguyen; Carol Feghali-Bostwick; Marina Miller; David H Broide; Rachel Soloff; Michael Croft Journal: J Immunol Date: 2020-09-21 Impact factor: 5.422